NLA
CCCC icon

Northern Lights Advisors’s C4 Therapeutics CCCC Stock Holding History

Northern Lights Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.4K Hold
12,930
– – 0.03% 69
2026
Q1 		$34K Hold
12,930
– – 0.02% 54
2025
Q4 		$24.7K Buy
+12,930
New +$30.6K 0.02% 52

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Lights Advisors's CCCC Position: Q2 2026 in Review

Northern Lights Advisors held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 12,930 shares worth $60.4K. The position accounts for 0.03% of the portfolio, ranked #69.

Northern Lights Advisors first reported a position in CCCC in Q4 2025 and has held it in 3 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Northern Lights Advisors held 12,930 shares of C4 Therapeutics worth $60.4K as of Q2 2026.
  • Northern Lights Advisors left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up 0.03% of Northern Lights Advisors's portfolio in Q2 2026, its #69 holding.
  • Northern Lights Advisors first reported a position in C4 Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Northern Lights Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.